JK-P3 是一种有效且具有广谱性的 VEGFR2 抑制剂，对 VEGFR2、FGFR1 和 FGFR3 的 IC₅₀ 分别为 7.83 μM、27 μM 和 5.18 μM。JK-P3 可以抑制 VEGF-A 刺激的 VEGFR2 激活和细胞内信号转导，也可以抑制内皮单层细胞迁移和血管生成，以及成纤维细胞生长因子受体激酶在体外的活性。JK-P3 具有抗血管生成的活性。

JK-P3 is a potent and pan VEGFR2 inhibitor, with IC 50 s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively. JK-P3 can inhibit VEGF-A-stimulated VEGFR2 activation and intracellular signalling, also inhibits endothelial monolayer wound closure and angiogenesis, as well as fibroblast growth factor receptor kinase activity in vitro. JK-P3 has anti-angiogenic activity.

Solid

VEGFR2 7.83 μM (IC50) FGFR1 27 μM (IC

JK-P3 (0.01-10 μM; 1 hour) inhibits VEGF-A-mediated VEGFR2 phosphorylation and downstream signalling.
JK-P3 (0.01-10 μM; 16 hours) dose not inhibit HUVEC cell proliferation at 0.01~1 μM, and shows slight inhibitory activity at 10 μM.
JK-P3 (1 and 10 μM; 1 hour) does not significantly inhibit VEGF-A-stimulated endothelial tube formation at 1 μM, but almost completely inhibits the ability of endothelial cells to form into elongated hollow tubes in the presence of VEGF-A at 10 μM. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

[1]. Kankanala J, et al. A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis. Br J Pharmacol. 2012;166(2):737-748.

In Vitro: DMSO : 50 mg/mL (154.63 mM; ultrasonic and warming and heat to 60°C)配制储备液